Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today
Last Friday, Adaptimmune's shares rocketed higher on the heels of a positive clinical update for its experimental T-cell therapy platform, which was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting.